Genomate Health

Name: Genomate Health
Brand: Genomate Health

AI Native

The right drug. The first time. Every time.TM Pioneering Digital Drug Assignment for Precision Oncology.

Est 2022|Raised $12.6M

LinkedIn 2K|Website|FTEs 31|HQ Cambridge, Massachusetts, US

01Competitive Landscape

Narrative analysis

Differentiation themes: - Genomate: Positions itself around knowledge-based reasoning that synthesizes the full molecular profile into ranked therapies with interpretable reasoning. - Tempus / Guardant / Foundation / Caris: Often bundle testing and reporting, with extensive commercial-scale data networks, payer engagements, and diagnostic logistics. Where competitors may excel relative to Genomate: - Market penetration and clinician familiarity: Established diagnostic labs benefit from broader clinician exposure and adoption. - Reimbursement pathways: Larger diagnostic firms often have more developed payer engagement and billing models. - Operational scale: Sample logistics, CLIA/CAP lab operations (where applicable), and standardized national workflows. Where Genomate may offer advantages if vendor claims are validated: - Actionability across complex mutation combinations: If the DDA approach demonstrably improves therapy selection beyond standard reporting. - Interpretability: If clinicians can review and audit reasoning rather than relying on opaque model outputs. - European operational footprint via the Oncompass acquisition, which may facilitate diagnostics and decision-support integration in the region. Adoption / market share signals: No reliable market share figures were identified in public sources. Company announcements and transaction activity indicate expansion efforts but do not confirm scale.

	Genomate Health (Genomate®)	Tempus	Guardant Health
Starting Price	Not publicly listed	Not publicly listed for many offerings; testing often billed via clinical lab model	Not publicly listed (generally lab testing / payer model)
Best For	Organizations seeking an interpretable computational therapy ranking that synthesizes the full molecular profile; can be used alongside NGS testing	Organizations seeking integrated testing, data platforms, and trial-matching services	Organizations prioritizing liquid biopsy workflows, monitoring, and broad clinical adoption
Key Strength	Knowledge-based computational reasoning and a public ISO 27001 certification; acquisition expands EU operations	Scale, broad commercial footprint, FDA-cleared tests in portfolio, large clinical data assets	Well-known liquid biopsy brand with monitoring use cases and wide clinical recognition
Key Weakness	Limited public third-party reviews; pricing not transparent; integration and validation may require buyer effort; limited public enterprise feature documentation	Complex enterprise sales and contracting; costs and integration effort can be significant	May be less focused on full-profile therapy ranking depending on product scope; specimen context is important

01Competitive Landscape

Narrative analysis

Differentiation themes:

Genomate: Positions itself around knowledge-based reasoning that synthesizes the full molecular profile into ranked therapies with interpretable reasoning.
Tempus / Guardant / Foundation / Caris: Often bundle testing and reporting, with extensive commercial-scale data networks, payer engagements, and diagnostic logistics.

Where competitors may excel relative to Genomate:

Market penetration and clinician familiarity: Established diagnostic labs benefit from broader clinician exposure and adoption.
Reimbursement pathways: Larger diagnostic firms often have more developed payer engagement and billing models.
Operational scale: Sample logistics, CLIA/CAP lab operations (where applicable), and standardized national workflows.

Where Genomate may offer advantages if vendor claims are validated:

Actionability across complex mutation combinations: If the DDA approach demonstrably improves therapy selection beyond standard reporting.
Interpretability: If clinicians can review and audit reasoning rather than relying on opaque model outputs.
European operational footprint via the Oncompass acquisition, which may facilitate diagnostics and decision-support integration in the region.

Adoption / market share signals: No reliable market share figures were identified in public sources. Company announcements and transaction activity indicate expansion efforts but do not confirm scale.

	Genomate Health (Genomate®)	Tempus	Guardant Health
Starting Price	Not publicly listed	Not publicly listed for many offerings; testing often billed via clinical lab model	Not publicly listed (generally lab testing / payer model)
Best For	Organizations seeking an interpretable computational therapy ranking that synthesizes the full molecular profile; can be used alongside NGS testing	Organizations seeking integrated testing, data platforms, and trial-matching services	Organizations prioritizing liquid biopsy workflows, monitoring, and broad clinical adoption
Key Strength	Knowledge-based computational reasoning and a public ISO 27001 certification; acquisition expands EU operations	Scale, broad commercial footprint, FDA-cleared tests in portfolio, large clinical data assets	Well-known liquid biopsy brand with monitoring use cases and wide clinical recognition
Key Weakness	Limited public third-party reviews; pricing not transparent; integration and validation may require buyer effort; limited public enterprise feature documentation	Complex enterprise sales and contracting; costs and integration effort can be significant	May be less focused on full-profile therapy ranking depending on product scope; specimen context is important

Genomate Health

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map